Blog
FDA Grants Accelerated Approval to Jemperli for Rectal Cancer: Immunotherapy Alone, Without Chemo, Radiation, or Surgery (Copy)
On October 16, 2026, the FDA converted Keytruda's approval for TMB-high solid tumors from accelerated to full — and raised the cutoff from 10 to 13 mutations per megabase. Here is what tumor mutational burden means, why the line moved, and what it means if your score was 10, 11, or 12.
FDA Grants Accelerated Approval to Jemperli for Rectal Cancer: Immunotherapy Alone, Without Chemo, Radiation, or Surgery
On October 19, 2026, the FDA granted accelerated approval to Jemperli (dostarlimab) — immunotherapy alone — for adults with stage II or III MSI-H/dMMR rectal cancer. In the AZUR-1 study, nearly half of patients had no detectable cancer a full year after treatment, and many avoided chemotherapy, radiation, and surgery. Here is what the news means, in plain language.
FDA Approves Immunotherapy Plus Chemotherapy for Stage III Colon Cancer: What Patients Need to Know
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) plus chemotherapy after surgery for stage III colon cancer with deficient mismatch repair (dMMR). In the ATOMIC trial, the combination cut the risk of the cancer coming back or death by 50%. Here is what the news means for patients and caregivers, in plain language.